Research And Development
Europe
Health

AstraZeneca

$39.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (0.93%) Today
+$0.11 (0.29%) After Hours

Why Robinhood?

You can buy or sell AstraZeneca and other stocks, options, ETFs, and crypto commission-free!

About

AstraZeneca PLC, also called AstraZeneca, is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Read More Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
64,400
Headquarters
Cambridge, Cambridgeshire
Founded
1992
Market Cap
98.95B
Price-Earnings Ratio
41.16
Dividend Yield
3.61
Average Volume
4.58M
High Today
$39.32
Low Today
$38.91
Open Price
$39.01
Volume
1.34M
52 Week High
$43.30
52 Week Low
$34.38

Collections

Research And Development
Europe
Health
Manufacturing
Cancer Prevention
Biotechnology
Medical
Biopharmaceutical

News

Seeking AlphaMay 21

An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market

AstraZeneca (AZN) announced that it had received approval for Qternmet XR as an oral adjunct treatment to diet and exercise for glycemic control in adults with type 2 diabetes (T2D). This is good news for the company because it has already received approval for a doublet therapy for the very same patient population.

106
MarketWatchMay 20

Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices

As Washington aims to rein in soaring drug prices, the spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.

2
Seeking AlphaMay 20

AstraZeneca's Symbicort Turbuhaler shows value proposition in real-world asthma study

New data from Novel START, an open-label real-world study of AstraZeneca's (NYSE:AZN) Symbicort Turbuhaler (budesonide/formoterol) in patients with mild asthma showed a treatment advantage compared to two commonly used regimens.

44

Earnings

$0.29
$0.72
$1.15
$1.58
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
$0.89 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.